Effects of Royal Jelly Supplementation in Chronic Kidney Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversidade Federal Fluminense
About this trial
The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with CKD undergoing hemodialysis for more than 6 months
patients with arteriovenous fistula (AVF) as vascular access.
Disqualifiers
pregnant,
lactating,
smoker
patients using antibiotics and antioxidant supplements in the last three months
Trial design
Design model
Parallel
Treatments tested in this trial
Real Jelly
Dietary supplementParticipants will receive 500mg of royal jelly capsules per day for two months.
Placebo
Dietary supplementParticipants will receive 500mg of placebo capsules per day for two months.
Treatment groups
30 Participants
are divided into 2 treatment groupsGroup A: Real Jelly GroupExperimental treatment 1 intervention
Group B: Placebo groupPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in inflammatory biomarkers
Changes in the mRNA levels of Nrf2, Keap1, Bach1, NLPR3, NF-kB, HO-1, NQO1, p14, p16, p21 and p53 as well as VCAM, ICAM and E-selectin and TLR-4, TNFR and AhR receptors, which will be evaluated from peripheral blood mononuclear cells.
Time frame
6 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov